Rapidly growing lung health company aims to redefine early diagnosis and precision lung cancer care using multi-modal artificial intelligence (AI). Optellum, a global leader in
Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive
The non-profit consortium is developing publicly accessible advanced AI-based drug discovery software tools OpenFold, a non-profit AI research consortium dedicated to creating free, open-source software tools
MPM BioImpact, a biotechnology investment firm creating and investing in innovative companies seeking to deliver transformative therapies to patients, announced that Brian Shuster will join
Jumo Health – a global provider of age-appropriate, culturally relevant medical education resources – announced it is a finalist for the Fierce DEI Award for helping
Fuel up with free Health Tech Insights
